Context Therapeutics (NASDAQ:CNTX - Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Context Therapeutics to post earnings of ($0.05) per share for the quarter.
Context Therapeutics Stock Performance
Shares of CNTX opened at $0.69 on Thursday. The stock has a fifty day moving average of $0.91 and a two-hundred day moving average of $1.52. The company has a market capitalization of $51.75 million, a PE ratio of -0.76 and a beta of 2.06. Context Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $2.75.
Analyst Ratings Changes
A number of research firms have recently commented on CNTX. Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. JMP Securities began coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective for the company. Finally, D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Wednesday, January 15th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $6.33.
Read Our Latest Analysis on Context Therapeutics
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
